{"success":true,"data":{"pressRelease":{"id":"148426","rtpr_id":"nPnc184y8a-20260921","ticker":"ABBV","exchange":"NYSE","all_tickers":["ABBV"],"title":"AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery","author":"PR Newswire","published_at":"2026-09-21T12:00:05.655Z","article_body":"AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery\nPR Newswire\n\nNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026\n\n * Multi-year partnership applies Iambic's AI platform to speed up small molecule\ndrug discovery in immunology, neuroscience and oncology\n * Companies to pursue programs with both first-in-class and best-in-class\npotential, combining Iambic's molecular superintelligence platform with\nAbbVie's therapeutic area expertise\nNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- AbbVie\n(NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company\ndeveloping novel medicines through its AI-driven discovery and development\nplatform, today announced a multi-year collaboration to accelerate the\ndiscovery and development of small molecule therapies with first-in-class and\nbest-in-class potential across immunology, neuroscience and oncology. The\ncompanies will leverage Iambic's AI platform to improve the efficiency and\nsuccess of identifying promising new drug candidates.\n\n\"We are excited about the purpose-built AI capabilities Iambic is bringing to\nour Discovery scientists,\" said Nicholas Donoghoe, M.D., executive vice\npresident and chief business and strategy officer, AbbVie. \"We believe AI will\nbe a powerful catalyst for scientific innovation across AbbVie. By equipping\nour teams with fit-for-purpose AI solutions, we can accelerate discovery,\nexpand what is possible in R&D and significantly advance our commitment to\nmaking a remarkable impact for patients.\"\n\n\"Combining Iambic's platform with the drug-hunting expertise of AbbVie\nscientists can help us make more precise decisions about the molecules we\npursue,\" said Jonathon Sedgwick, Ph.D., senior vice president and global head\nof discovery research, AbbVie. \"The goal of our collaboration with Iambic is\nto design better molecules more efficiently and improve our probability of\nsuccess, ultimately to deliver breakthrough medicines for patients sooner.\"\n\nIn traditional small molecule discovery, scientists evaluate dozens of\nproperties for each candidate individually. Iambic's molecular\nsuperintelligence platform is powered by Enchant and NeuralPLexer,\ntechnologies designed to optimize the full range of candidate properties\nsimultaneously, increasing the chance of making better molecules while\nreducing drug discovery timelines.\n\nThe collaboration will utilize Enchant v3, Iambic's next-generation multimodal\ntransformer model that combines biomedical data modalities from across the\ndrug discovery process and enables many drug design hypotheses to be tested in\nparallel and at scale. Enchant v3 is designed to achieve industry-leading\nprediction accuracy across drug discovery and development and is trained on\nover 6,000 molecular properties.\n\n\"Iambic's mission is to make better technology for better medicines — in our\nown hands and with partners,\" said Tom Miller, Ph.D., Co-Founder and CEO,\nIambic. \"We are eager to bring Iambic's molecular superintelligence platform\nto bear alongside AbbVie's world-class team to address unmet patient need. We\nanticipate an impactful collaboration — for Iambic, for AbbVie, and for the\npatients we serve.\"\n\nUnder the terms of the collaboration, Iambic will receive an upfront payment\nand is eligible to receive success-based milestone payments and tiered\nroyalties on net sales from products generated from the collaboration.\n\nAbout AI@AbbVie\n\nAI@AbbVie is AbbVie's enterprise approach to using artificial intelligence\n(AI) to advance scientific innovation, strengthen business outcomes and\nimprove how medicines are discovered, developed and delivered to patients. AI\nis an important enabler of our mission, helping employees enhance\nproductivity, strengthen decision-making and accelerate progress across\nR&D, operations and other core business functions. Guided by human\nexpertise, responsible governance and a commitment to meaningful impact, we\nare embedding AI across the enterprise to accelerate innovation and help\nimprove patients' lives.\n\nAbout AbbVie\n\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2617218872&u=http%3A%2F%2Fwww.abbvie.com%2F&a=www.abbvie.com)\n. Follow @abbvie on LinkedIn,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=4033659240&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&a=LinkedIn%2C)\n Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2437864202&u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=3446249772&u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&a=Instagram)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2464857560&u=https%3A%2F%2Ftwitter.com%2Fabbvie&a=X)\n and YouTube.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=599963493&u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&a=YouTube.)\n\nAbout Iambic Therapeutics, Inc.\n\nIambic's mission is to make better technology for better medicines. By\nutilizing molecular superintelligence — integrating proprietary AI with\nautomated, scalable chemistry and biology experimentation — our platform is\ndesigned to address the totality of drug discovery and development. The\nutility of our platform has been demonstrated by the discovery of a novel drug\ncandidate advanced to clinic in approximately two years, along with a diverse\npreclinical pipeline. Our leading AI technologies include Enchant and\nNeuralPLexer for multimodal endpoint prediction designed to improve the speed,\nprecision, and success rates of drug discovery and clinical development. At\nIambic, we are building an engine that is designed to power the future of\nmedicine. | iambic.ai\n\nAbbVie Forward-Looking Statements\n\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n AbbVie Media:                 AbbVie Investors:\n\nCatherine Langel\nLiz Shea\n\ncatherine.langel@abbvie.com\nliz.shea@abbvie.com\n\nIambic Investors:\n\nIambic Media:                Tiao Guan\n\nAmanda Guisbond\ntiao.guan@iambic.ai\n amanda.guisbond@iambic.ai\n\nView original\ncontent:https://www.prnewswire.com/news-releases/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-302883724.html\n(https://www.prnewswire.com/news-releases/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-302883724.html)\n\nSOURCE AbbVie\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnc184y8a-20260921","title":"AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery","author":"PR Newswire","ticker":"ABBV","created":"2026-09-21T12:00:05.655Z","tickers":["ABBV"],"exchange":"NYSE","article_body":"AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery\nPR Newswire\n\nNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026\n\n * Multi-year partnership applies Iambic's AI platform to speed up small molecule\ndrug discovery in immunology, neuroscience and oncology\n * Companies to pursue programs with both first-in-class and best-in-class\npotential, combining Iambic's molecular superintelligence platform with\nAbbVie's therapeutic area expertise\nNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- AbbVie\n(NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company\ndeveloping novel medicines through its AI-driven discovery and development\nplatform, today announced a multi-year collaboration to accelerate the\ndiscovery and development of small molecule therapies with first-in-class and\nbest-in-class potential across immunology, neuroscience and oncology. The\ncompanies will leverage Iambic's AI platform to improve the efficiency and\nsuccess of identifying promising new drug candidates.\n\n\"We are excited about the purpose-built AI capabilities Iambic is bringing to\nour Discovery scientists,\" said Nicholas Donoghoe, M.D., executive vice\npresident and chief business and strategy officer, AbbVie. \"We believe AI will\nbe a powerful catalyst for scientific innovation across AbbVie. By equipping\nour teams with fit-for-purpose AI solutions, we can accelerate discovery,\nexpand what is possible in R&D and significantly advance our commitment to\nmaking a remarkable impact for patients.\"\n\n\"Combining Iambic's platform with the drug-hunting expertise of AbbVie\nscientists can help us make more precise decisions about the molecules we\npursue,\" said Jonathon Sedgwick, Ph.D., senior vice president and global head\nof discovery research, AbbVie. \"The goal of our collaboration with Iambic is\nto design better molecules more efficiently and improve our probability of\nsuccess, ultimately to deliver breakthrough medicines for patients sooner.\"\n\nIn traditional small molecule discovery, scientists evaluate dozens of\nproperties for each candidate individually. Iambic's molecular\nsuperintelligence platform is powered by Enchant and NeuralPLexer,\ntechnologies designed to optimize the full range of candidate properties\nsimultaneously, increasing the chance of making better molecules while\nreducing drug discovery timelines.\n\nThe collaboration will utilize Enchant v3, Iambic's next-generation multimodal\ntransformer model that combines biomedical data modalities from across the\ndrug discovery process and enables many drug design hypotheses to be tested in\nparallel and at scale. Enchant v3 is designed to achieve industry-leading\nprediction accuracy across drug discovery and development and is trained on\nover 6,000 molecular properties.\n\n\"Iambic's mission is to make better technology for better medicines — in our\nown hands and with partners,\" said Tom Miller, Ph.D., Co-Founder and CEO,\nIambic. \"We are eager to bring Iambic's molecular superintelligence platform\nto bear alongside AbbVie's world-class team to address unmet patient need. We\nanticipate an impactful collaboration — for Iambic, for AbbVie, and for the\npatients we serve.\"\n\nUnder the terms of the collaboration, Iambic will receive an upfront payment\nand is eligible to receive success-based milestone payments and tiered\nroyalties on net sales from products generated from the collaboration.\n\nAbout AI@AbbVie\n\nAI@AbbVie is AbbVie's enterprise approach to using artificial intelligence\n(AI) to advance scientific innovation, strengthen business outcomes and\nimprove how medicines are discovered, developed and delivered to patients. AI\nis an important enabler of our mission, helping employees enhance\nproductivity, strengthen decision-making and accelerate progress across\nR&D, operations and other core business functions. Guided by human\nexpertise, responsible governance and a commitment to meaningful impact, we\nare embedding AI across the enterprise to accelerate innovation and help\nimprove patients' lives.\n\nAbout AbbVie\n\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2617218872&u=http%3A%2F%2Fwww.abbvie.com%2F&a=www.abbvie.com)\n. Follow @abbvie on LinkedIn,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=4033659240&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&a=LinkedIn%2C)\n Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2437864202&u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=3446249772&u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&a=Instagram)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=2464857560&u=https%3A%2F%2Ftwitter.com%2Fabbvie&a=X)\n and YouTube.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778025-1&h=599963493&u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&a=YouTube.)\n\nAbout Iambic Therapeutics, Inc.\n\nIambic's mission is to make better technology for better medicines. By\nutilizing molecular superintelligence — integrating proprietary AI with\nautomated, scalable chemistry and biology experimentation — our platform is\ndesigned to address the totality of drug discovery and development. The\nutility of our platform has been demonstrated by the discovery of a novel drug\ncandidate advanced to clinic in approximately two years, along with a diverse\npreclinical pipeline. Our leading AI technologies include Enchant and\nNeuralPLexer for multimodal endpoint prediction designed to improve the speed,\nprecision, and success rates of drug discovery and clinical development. At\nIambic, we are building an engine that is designed to power the future of\nmedicine. | iambic.ai\n\nAbbVie Forward-Looking Statements\n\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n AbbVie Media:                 AbbVie Investors:\n\nCatherine Langel\nLiz Shea\n\ncatherine.langel@abbvie.com\nliz.shea@abbvie.com\n\nIambic Investors:\n\nIambic Media:                Tiao Guan\n\nAmanda Guisbond\ntiao.guan@iambic.ai\n amanda.guisbond@iambic.ai\n\nView original\ncontent:https://www.prnewswire.com/news-releases/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-302883724.html\n(https://www.prnewswire.com/news-releases/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-302883724.html)\n\nSOURCE AbbVie\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-21T12:00:05.705034488Z","server_sent_at_ms":1789992005705},"received_at":"2026-09-21T12:00:05.760Z","source_url":"https://www.prnewswire.com/news-releases/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-302883724.html"},"analysis":{"id":"137117","press_release_id":"148426","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Financial terms not disclosed — upfront payment amount and royalty economics unspecified, so the deal's value cannot be assessed"],"eventType":"partnership","narrative":"AbbVie and Iambic Therapeutics announced a multi-year collaboration to apply Iambic's AI-driven discovery platform to small molecule drug discovery across immunology, neuroscience and oncology.\n\nThe partnership will use Iambic's Enchant v3, a next-generation multimodal transformer trained on over 6,000 molecular properties, alongside NeuralPLexer, to test drug-design hypotheses in parallel and shorten discovery timelines.\n\nFinancial terms were not disclosed: Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated by the collaboration.\n\nFor AbbVie, the deal is an R&D-productivity play under its AI@AbbVie initiative rather than a near-term earnings driver.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"AbbVie adds Iambic's AI discovery platform across immunology, neuroscience and oncology; no financial terms, so frame as an R&D-productivity story rather than a numbers event."},"keyFigures":{"customDimensions":{"collaboration_scope":"multi-year","molecular_properties_trained":"over 6,000"}},"quotedText":"We believe AI will\nbe a powerful catalyst for scientific innovation across AbbVie.","namedEntities":{"people":[{"name":"Nicholas Donoghoe, M.D.","role":"Executive Vice President and Chief Business and Strategy Officer, AbbVie"},{"name":"Jonathon Sedgwick, Ph.D.","role":"Senior Vice President and Global Head of Discovery Research, AbbVie"},{"name":"Tom Miller, Ph.D.","role":"Co-Founder and CEO, Iambic"}],"products":["Enchant v3","Enchant","NeuralPLexer","AI@AbbVie"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer and collaboration partner"},{"name":"Iambic Therapeutics, Inc.","relationship":"collaboration partner (private AI drug-discovery company)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A multi-year strategic AI drug-discovery collaboration, but no financial terms disclosed and all programs are discovery-stage, so there is no near-term revenue or earnings impact for AbbVie. Meaningful for R&D productivity narrative, not market-moving."},"tickerRelevance":{"others":[],"primary":"ABBV"},"globalImportance":32,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap S&P 100 household brand","eventGravity":"multi-year strategic partnership with no disclosed financial terms","sectorWeight":"pharma R&D productivity / AI drug discovery","householdBrandBoost":true,"nearTermFinancialImpact":"none disclosed"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"AbbVie and Iambic Therapeutics announced a multi-year collaboration to apply Iambic's AI-driven discovery platform to small molecule drug discovery across immunology, neuroscience and oncology.\n\nThe partnership will use Iambic's Enchant v3, a next-generation multimodal transformer trained on over 6,000 molecular properties, alongside NeuralPLexer, to test drug-design hypotheses in parallel and shorten discovery timelines.\n\nFinancial terms were not disclosed: Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated by the collaboration.\n\nFor AbbVie, the deal is an R&D-productivity play under its AI@AbbVie initiative rather than a near-term earnings driver.","key_figures":{"customDimensions":{"collaboration_scope":"multi-year","molecular_properties_trained":"over 6,000"}},"named_entities":{"people":[{"name":"Nicholas Donoghoe, M.D.","role":"Executive Vice President and Chief Business and Strategy Officer, AbbVie"},{"name":"Jonathon Sedgwick, Ph.D.","role":"Senior Vice President and Global Head of Discovery Research, AbbVie"},{"name":"Tom Miller, Ph.D.","role":"Co-Founder and CEO, Iambic"}],"products":["Enchant v3","Enchant","NeuralPLexer","AI@AbbVie"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer and collaboration partner"},{"name":"Iambic Therapeutics, Inc.","relationship":"collaboration partner (private AI drug-discovery company)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-21T12:13:39.380Z","global_importance":32,"audience_relevance":45,"importance_components":{"tickerTier":"mega-cap S&P 100 household brand","eventGravity":"multi-year strategic partnership with no disclosed financial terms","sectorWeight":"pharma R&D productivity / AI drug discovery","householdBrandBoost":true,"nearTermFinancialImpact":"none disclosed"}},"durationMs":169215,"modelName":"glm-5.3-flash"}}